In:
Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 28, No. 20 ( 2021-07-02), p. 4004-4022
Abstract:
Obesity is a major health concern for a growing fraction of the population, as its prevalence
and related metabolic disorders are not fully understood. Over the last decade, many attempts have been undertaken to understand the mechanisms at the basis of this condition, in
which the accumulation of fat occurring in adipose tissue leads to the pathogenesis of obesity- related disorders. Among the most recent studies, those on Peroxisome Proliferator Activated
Receptors (PPARs) revealed that these nuclear receptor proteins acting as transcription factors, among others, regulate the expression of genes involved in energy, lipid, and glucose
metabolisms, and chronic inflammation. The three different isotypes of PPARs, with different tissue expression and ligand binding specificity, exert similar or overlapping functions directly
or indirectly linked to obesity. In this study, we reviewed the available scientific reports concerning the PPARs structure and functions, especially in obesity, considering both natural and
synthetic ligands and their role in the therapy of obesity and obesity-associated disorders. On the whole, the collected data suggest that there are both natural and synthetic compounds that
show beneficial and promising activity as PPAR agonists in chronic diseases related to obesity.
Type of Medium:
Online Resource
ISSN:
0929-8673
DOI:
10.2174/1570162X18666201123114934
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2021
SSG:
15,3
Permalink